Busulfan and Cyclophosphamide Followed By Allogeneic Hematopoietic Cell Transplantation In Patients With Hematological Malignancies
This is a single arm trial to evaluate the efficacy of busulfan and cyclophosphamide
followed by an allogeneic hematopoietic stem cell transplant (HSCT) in the treatment of
hematological malignancies. The intent of this study is to provide a protocol that will use
unmanipulated allogeneic hematopoietic stem cells from related and unrelated donors after a
common preparative regimen. Results will be compared to historical controls.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Disease Free Survival
The length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.
Margaret L. MacMillan, M.D.
Masonic Cancer Center, University of Minnesota
United States: Institutional Review Board
|Masonic Cancer Center, University of Minnesota||Minneapolis, Minnesota 55455|